Presima Has Increased General Growth Pptys New (GGP) Stake By $2.74 Million, Neurotrope (NTRP) Shorts Down By 13.43%

June 30, 2017 - By Henry Gaston

Neurotrope Incorporated (NASDAQ:NTRP) had a decrease of 13.43% in short interest. NTRP’s SI was 291,400 shares in June as released by FINRA. Its down 13.43% from 336,600 shares previously. With 793,500 avg volume, 0 days are for Neurotrope Incorporated (NASDAQ:NTRP)’s short sellers to cover NTRP’s short positions. The SI to Neurotrope Incorporated’s float is 5.79%. It closed at $8.72 lastly. It is down 0.00% since June 30, 2016 and is . It has underperformed by 16.70% the S&P500.

Presima Inc increased General Growth Pptys Inc New (GGP) stake by 3.55% reported in 2016Q4 SEC filing. Presima Inc acquired 114,200 shares as General Growth Pptys Inc New (GGP)’s stock declined 8.47%. The Presima Inc holds 3.33M shares with $83.21M value, up from 3.22 million last quarter. General Growth Pptys Inc New now has $20.78B valuation. It closed at $23.81 lastly. It is down 11.69% since June 30, 2016 and is downtrending. It has underperformed by 28.39% the S&P500.

Investors sentiment decreased to 0.92 in 2016 Q4. Its down 0.18, from 1.1 in 2016Q3. It dived, as 64 investors sold GGP shares while 121 reduced holdings. 37 funds opened positions while 134 raised stakes. 742.41 million shares or 7.29% less from 800.79 million shares in 2016Q3 were reported. Millennium Mngmt Ltd Com has invested 0.14% of its portfolio in GGP Inc (NYSE:GGP). Adage Cap Prtn Group Inc Ltd reported 0.06% of its portfolio in GGP Inc (NYSE:GGP). Teachers Insur And Annuity Association Of America invested in 0.45% or 528,439 shares. Robeco Institutional Asset Bv has 0.05% invested in GGP Inc (NYSE:GGP) for 269,711 shares. Aqr Cap Management Ltd holds 0.02% or 596,651 shares in its portfolio. Nomura Asset Limited reported 0.22% in GGP Inc (NYSE:GGP). Henderson Group Inc Public Ltd reported 0.11% of its portfolio in GGP Inc (NYSE:GGP). Virginia Retirement System Et Al holds 765,280 shares or 0.27% of its portfolio. Aberdeen Asset Mgmt Public Limited Liability Uk owns 0.01% invested in GGP Inc (NYSE:GGP) for 155,123 shares. Soros Fund Mngmt holds 0.01% in GGP Inc (NYSE:GGP) or 13,500 shares. Asset One has invested 0.15% in GGP Inc (NYSE:GGP). Suntrust Banks Inc reported 10,499 shares or 0% of all its holdings. Meiji Yasuda Life Insurance has invested 0.04% in GGP Inc (NYSE:GGP). The Ontario – Canada-based Canada Pension Plan Invest Board has invested 0.04% in GGP Inc (NYSE:GGP). Comerica Bancshares stated it has 180,378 shares or 0.04% of all its holdings.

Among 16 analysts covering General Growth Properties (NYSE:GGP), 9 have Buy rating, 1 Sell and 6 Hold. Therefore 56% are positive. General Growth Properties had 30 analyst reports since August 4, 2015 according to SRatingsIntel. The company was upgraded on Friday, October 14 by Sandler O’Neill. The firm has “Hold” rating given on Friday, August 28 by Zacks. Zacks upgraded the shares of GGP in report on Tuesday, August 11 to “Sell” rating. The firm has “Neutral” rating given on Wednesday, August 31 by Hilliard Lyons. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 3. On Tuesday, August 4 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Deutsche Bank on Wednesday, August 17 with “Buy”. The company was downgraded on Monday, January 9 by Deutsche Bank. The stock has “Buy” rating by S&P Research on Wednesday, August 12. Evercore maintained the shares of GGP in report on Tuesday, September 8 with “Buy” rating.

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical firm with its product candidates in pre-clinical and clinical development. The company has market cap of $77.50 million. The Firm is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease , which is in the clinical testing stage. It currently has negative earnings. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing.